Defensive Cash Stance Pushes Rev Shark Toward BBIO and SOFI Bets
Investors are nervous ahead of the Fed decision and major earnings. Rev Shark has raised cash to about 45% and will wait for tonight’s results before new moves, having added BridgeBio Pharma after a patent-litigation resolution and eyeing SoFi Technologies after an earnings-driven selloff, while noting SoFi’s tech platform revenue fell 27% year over year. He remains long Alphabet (GOOGL) and BBIO, expecting earnings and energy-cost inflation signals to drive the next market moves.